Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

@article{Eichhorn2008Phosphatidylinositol3H,
  title={Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.},
  author={P. Eichhorn and M. Gili and M. Scaltriti and V. Serra and M. Guzm{\'a}n and Wouter Nijkamp and R. Beijersbergen and V. Valero and J. Seoane and R. Bernards and J. Baselga},
  journal={Cancer research},
  year={2008},
  volume={68 22},
  pages={
          9221-30
        }
}
  • P. Eichhorn, M. Gili, +8 authors J. Baselga
  • Published 2008
  • Medicine
  • Cancer research
  • Small molecule inhibitors of HER2 are clinically active in women with advanced HER2-positive breast cancer who have progressed on trastuzumab treatment. However, the effectiveness of this class of agents is limited by either primary resistance or acquired resistance. Using an unbiased genetic approach, we performed a genome wide loss-of-function short hairpin RNA screen to identify novel modulators of resistance to lapatinib, a recently approved anti-HER2 tyrosine kinase inhibitor. Here, we… CONTINUE READING
    455 Citations
    PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells
    • 36
    • Highly Influenced
    mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb®)
    • 61
    Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib
    • 275
    • Highly Influenced
    • PDF
    An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models
    • 96
    • Highly Influenced
    Resistance to HER2-directed antibodies and tyrosine kinase inhibitors
    • 145

    References

    SHOWING 1-10 OF 47 REFERENCES
    NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
    • 724
    • PDF
    Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
    • 824
    • PDF
    Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
    • 699
    • PDF
    Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.
    • 448
    • Highly Influential
    • PDF
    A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
    • 1,419
    • PDF